Age-related macular degeneration (AMD) is the chief cause of severe and irreversible loss of vision in developed countries. The prevalence of AMD increases dramatically with age.
The early stage (or dry AMD) is associated with minimal visual impairment and is characterized by large drusen and pigmentary abnormalities in the macula. The late stage is a neovascular, exudative form. This so called exudative AMD includes serous or hemorrhagic detachment of retinal pigment epithelium and choroidal neovascularization leading to severe loss of vision (20/200 or worse). Patients with unilateral CNV (choroidal neovascularisation) have a significant risk of CNV developing in the second eye.
Choroidal blood flow is of great importance for normal visual function. Several reports have provided evidence suggesting that choroidal blood flow is decreased in subjects with AMD. In late stages of AMD angiogenesis leads to the formation of choroidal neovascularization that can cause severe visual impairment by disrupting normal macular function.
The purpose of this evaluation is to investigate a possible link between alterations in choroidal blood flow and the development of CNV and serous detachment in the fellow eye of patients with AMD and unilateral neovascular maculopathy. This longitudinal study may provide important findings with respect to natural history and visual prognosis of patients with neovascularized AMD.
Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Basic Science
- Masking: None (Open Label)
- Procedure: ocular blood flow measurement
- Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry
Arms, Groups and Cohorts
- Experimental: 1
- Observatory, longitudinal, 3-years follow up study
Clinical Trial Outcome Measures
- Choroidal blood flow (laser Doppler flowmetry)
- Fundus pulsation amplitude (laser interferometry)
Participating in This Clinical Trial
- Male or female patients with unilateral choroidal neovascular AMD and 2-4 risk factors for AMD in the fellow eye.
- Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant Ametropy < 4 dpt.
- Abuse of alcoholic beverages
- Participation in a clinical trial in the 3 weeks preceding the study
- Any signs of diabetic retinopathy
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Medical University of Vienna
- Overall Official(s)
- Leopold Schmetterer, Prof. Dr., Principal Investigator, Department of Clinical Pharmacology, Medical University of Vienna
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.